TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tarsus Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2024 was $-0.93 Mil. It means Tarsus Pharmaceuticals's inventory increased by $0.93 Mil from Dec. 2023 to Mar. 2024 .
Tarsus Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-3.11 Mil. It means Tarsus Pharmaceuticals's inventory increased by $3.11 Mil from Dec. 2022 to Dec. 2023 .
Tarsus Pharmaceuticals's Total Inventories for the quarter that ended in Mar. 2024 was $4.04 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Tarsus Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2024 was 197.04.
Inventory Turnover measures how fast the company turns over its inventory within a year. Tarsus Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.46.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Tarsus Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.13.
The historical data trend for Tarsus Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | -3.11 |
Tarsus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | -0.93 |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (NAS:TARS) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tarsus Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 3.5715 | / | 1.654 | * | 365 / 4 | |
= | 197.04 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Tarsus Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 1.654 | / | 3.5715 | |
= | 0.46 |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tarsus Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 3.5715 | / | 27.614 | |
= | 0.13 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
Rosemary A Crane | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
From GuruFocus
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 06-12-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By Value_Insider Value_Insider • 12-16-2022
By GlobeNewswire • 08-02-2023
By PurpleRose PurpleRose • 08-05-2022
By GuruFocus Research GuruFocus Editor • 12-23-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.